ClinicalTrials.gg
RecruitingNCT07940231Updated Nov 16, 2026

Prospective Study of Intraoperative Brain Tumor Photographs for Pathological and Molecular Classification

An observational study in Glioma (Diagnosis), sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Beijing Tiantan Hospital · Observational

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Glioma by Beijing Tiantan Hospital — 10 open to participants now, 11 under way, none of them phase 3. Glioma · Beijing Tiantan Hospital.

Started
2026
the only one that year
Observational
4 of 14
4 open now
Primary completion
2026-11
later than 7 of 10 live
Registered
14th of 14
by date

Among the 14 studies in Glioma by Beijing Tiantan Hospital, this one is the only one that started in 2026, is one of 4 observational ones, reaches primary completion later than 7 of the 10 other live ones, and was the 14th registered.

Glioma

1,453 studies on the registry are indexed under Glioma; 349 are open to participants now.

Browse Glioma studies →

Open to participants now

10 of the 14 studies in Glioma by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 267 Glioma studies recruiting now, 164 (61%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Glioma by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

This prospective observational cohort study will evaluate the diagnostic performance and workflow feasibility of a prespecified locked artificial intelligence model that analyzes smartphone-based natural-light gross images of fresh surgical tissue together with participant age. Approximately 400 consecutive adults undergoing initial surgery for suspected intracranial adult-type diffuse glioma will be enrolled at Beijing Tiantan Hospital, Capital Medical University, between July and September 2026. Images will be acquired before frozen-section processing according to a standardized operating procedure. Model outputs will be generated in silent mode and will not be shown to the surgical or pathology teams and will not alter diagnosis or treatment. The locked model score will be compared with the final IDH mutation reference standard derived from permanent histopathology, immunohistochemistry, and indicated molecular testing. The primary objective is to estimate patient-level discrimination for IDH-mutant versus IDH-wildtype tumors. Secondary objectives include fixed-threshold performance, precision-recall performance, calibration, end-to-end technical success, and prespecified model abstention, if an abstention rule is locked before enrollment.

Read the detailed description

Eligible participants will be enrolled consecutively, and a screening log will document all exclusions. Fresh ex vivo tumor tissue will be photographed before freezing. Images will be deidentified and linked through a participant-surgery-specimen-image hierarchy. The locked SNAP-IDH model will segment the tumor region of interest, permit blinded quality confirmation or editing, and combine frozen iBOT image features with age using a radial basis function support vector machine. The output is a research model score rather than a clinically calibrated absolute risk. A score of frozen yoden or will be classified as IDH-mutant. Model outputs will remain hidden from all clinical decision makers. No retraining, hyperparameter tuning, threshold selection, or recalibration will use the prospective cohort. Diagnostic accuracy will be analyzed at the participant level. Image-acquisition, segmentation, inference, and reference-standard failures will be retained in the study flow and reported separately from complete-case diagnostic performance.

03

Conditions studied

  • Glioma (Diagnosis)

Browse trials for

Keywords

  • Glioma
  • AI
  • IDH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Consecutive adults undergoing initial surgery for suspected intracranial adult diffuse glioma at the participating facility

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 years or older at enrollment.
  2. A newly presenting intracranial lesion is radiologically suspected to be an adult-type diffuse glioma, and the participant is scheduled to undergo initial surgical resection or at a participating site.
  3. The planned index surgery includes an attempt to collect fresh tumor tissue for standardized natural-light gross-image acquisition before freezing.
  4. Participants must be able and willing to provide written before any study-specific procedure.

Exclusion criteria

Exclusion Criteria

  1. Two or more radiologically distinct intracranial lesions identified on preoperative imaging.
  2. Radiotherapy or chemotherapy directed at the current intracranial lesion before the index surgery.
  3. Known recurrent disease or a previous tumor-directed surgical procedure for the current lesion.
  4. Primary spinal cord tumor, including a cervical spinal cord tumor.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Prospective Silent-Validation Cohort. Consecutive adults undergoing initial surgery for suspected i

    Diagnostic Test: Smartphone Nature-image AI prediction of IDH status (SNAP-IDH)

Interventions

  • Diagnostic testSmartphone Nature-image AI prediction of IDH status (SNAP-IDH)

    Consecutive adults undergoing initial surgery for suspected intracranial adult-type diffuse glioma will undergo standardized research imaging of fresh surgical tissue. Locked model outputs will not influence routine surgery, frozen-section assessment, permanent pathology, molecular testing, or treatment.

06

What researchers measure

Primary outcomes

  1. Patient-Level Area Under the Precision-Recall Curve of the Locked SNAP-IDH Score for IDH Mutation Status

    Area under the precision-recall curve (AUPRC) calculated using one locked SNAP-IDH score per patient and the final reference-standard isocitrate dehydrogenase (IDH) mutation status, with IDH-mutant status as the positive class. AUPRC ranges from 0 to 1, with higher values indicating better performance.

    Time frame: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.

Secondary outcomes

  1. Patient-Level Sensitivity of SNAP-IDH for IDH Mutation Status at the Prespecified Threshold

    Percentage of patients with reference-standard isocitrate dehydrogenase (IDH)-mutant status classified as IDH-mutant by SNAP-IDH at the prespecified, locked classification threshold. Sensitivity is calculated as true positives divided by the sum of true positives and false negatives, multiplied by 100.

    Time frame: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.

  2. Patient-Level Specificity of SNAP-IDH for IDH Mutation Status at the Prespecified Threshold

    Percentage of patients with reference-standard isocitrate dehydrogenase (IDH)-wildtype status classified as IDH-wildtype by SNAP-IDH at the prespecified, locked classification threshold. Specificity is calculated as true negatives divided by the sum of true negatives and false positives, multiplied by 100.

    Time frame: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.

  3. Patient-Level Brier Score of the Locked SNAP-IDH Predicted Probability for IDH Mutation Status

    Mean squared difference between each patient's locked SNAP-IDH predicted probability of isocitrate dehydrogenase (IDH) mutation and the final reference-standard status, coded as 1 for IDH-mutant and 0 for IDH-wildtype. The Brier score ranges from 0 to 1, with lower values indicating lower prediction error.

    Time frame: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Nov 2026, 4 months after the start.

Of 113 non-industry observational studies under Glioma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 104. This study's planned 4 months is below that.

Counting every sponsor, half of 123 studies reached it within 60 months; a quarter within 29 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 16, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940231
Responsible party
Yinyan Wang (Dr., Beijing Tiantan Hospital) — Principal investigator
First posted
Nov 16, 2026
Start date
Jul 1, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Nov 16, 2026

Study contacts

Yinyan Wang
Contact
tiantanyinyan@126.com
+86 13581698953

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion